Drugs / Hep B
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04054752 Comparator | May → Nov 2023 | breast carcinoma, colorectal adenocarcinoma, urinary bladder carcinoma | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hep B | “Day 1 Immunization Pre-NT-I7:Td and Polio Day 64, Immunization Post-NT-I7: Hep A#1, Hep B#1 Day 106: Hep B#2 (Optional) 6 Month Post NT-I7 Vaccines (Optional): Polio, Hep A#2,...” NCT04054752 ↗ |
| Modality | Vaccine | “Day 64, Immunization Post-NT-I7: Hep A#1, Hep B#1” NCT04054752 ↗ |